Print page Share page

About ponatinib.

Internally discovered at ARIAD, ponatinib is a BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT and the members of the FGFR, PDGFR and VEGFR families of kinases.

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue